Form 8-K - Current report:
SEC Accession No. 0000950170-24-126461
Filing Date
2024-11-13
Accepted
2024-11-13 17:00:08
Documents
12
Period of Report
2024-11-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jagx-20241113.htm   iXBRL 8-K 44412
2 EX-10.1 jagx-ex10_1.htm EX-10.1 24798
  Complete submission text file 0000950170-24-126461.txt   186745

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT jagx-20241113.xsd EX-101.SCH 24902
14 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20241113_htm.xml XML 4708
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 241455415
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)